Key clinical milestones achieved, including first patient treatment in primary prostate cancer study, and SEK 54.8 million raised to support ongoing trials. Net loss widened year-over-year, but cash flow and equity position improved after the rights issue.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.